Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations

NCT ID: NCT01903148

Last Updated: 2014-01-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

455 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the impact of the last recommendations of the European Anemia Working Group ERBP in the anemia management in the achievement of the therapeutic goal of Hb 11-12 g/dL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ANEMIA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults patients with anemia secondary to chronic kidney disease (CKD) not on dialysis.
* Patients starting anemia treatment (naïve) after six months of the last recommendations of the European Anemia Working Group ERBP (January 2011).
* Patients in treatment who changed from previous ESA treatment since January 2011 (converted patients

Exclusion Criteria

* Patients in Erythropoiesis Stimulating Agents (ESA) dose adjustment period.
* Kidney transplant patients.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundación Senefro

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alberto Martinez Castelao, Doctor

Role: PRINCIPAL_INVESTIGATOR

Hospital Bellvitge

Aleix Cases, Doctor

Role: PRINCIPAL_INVESTIGATOR

Hospital Clinic of Barcelona

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Puerto Real

Cadiz, Andalusia, Spain

Site Status

Hospital de Jerez

Jerez de la Frontera, Andalusia, Spain

Site Status

Clínico V. Victoria

Málaga, Andalusia, Spain

Site Status

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital Universitario Nuestra Señora De Candelaria

Santa Cruz de Tenerife, Canary Islands, Spain

Site Status

Hospital Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Virgen de la Luz

Toledo, Castille-La Mancha, Spain

Site Status

Fundación Puigvert

Barcelona, Catalonia, Spain

Site Status

Hospital Bellvige

Barcelona, Catalonia, Spain

Site Status

Hospital Bellvitge

Barcelona, Catalonia, Spain

Site Status

Hospital Clinic

Barcelona, Catalonia, Spain

Site Status

Hospital Germans Trias i Pujol

Barcelona, Catalonia, Spain

Site Status

Hospital Valld'Hebron

Barcelona, Catalonia, Spain

Site Status

Sagrat Cor

Barcelona, Catalonia, Spain

Site Status

Clinica Girona

Girona, Catalonia, Spain

Site Status

Hospital Josep Trueta

Girona, Catalonia, Spain

Site Status

Arquitecto Marcide

Ferrol, Galicia, Spain

Site Status

Complexo Hospitalario de Ourense

Ourense, Galicia, Spain

Site Status

Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, Galicia, Spain

Site Status

Hospital 12 de Octubre

Madrid, Madrid, Spain

Site Status

Hospital Clínico San Carlos

Madrid, Madrid, Spain

Site Status

Hospital Gregorio Marañón

Madrid, Madrid, Spain

Site Status

Hospital La Paz

Madrid, Madrid, Spain

Site Status

Hospital La Princesa

Madrid, Madrid, Spain

Site Status

Hospital General de Alicante

Alicante, Valencia, Spain

Site Status

Hospital de Castellón

Castellon, Valencia, Spain

Site Status

Hospital Clínico de Valencia

Valencia, Valencia, Spain

Site Status

Hospital Dr. Peset

Valencia, Valencia, Spain

Site Status

Hospital La Fe

Valencia, Valencia, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SEN-AEE-2011-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.